Frazier Life Sciences Management, L.P. Krystal Biotech, Inc. Transaction History

Frazier Life Sciences Management, L.P.

$1.9 Billion
Q2 2025

A detailed history of Frazier Life Sciences Management, L.P. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 688,460 shares of KRYS stock, worth $98.9 Million. This represents 4.99% of its overall portfolio holdings.

Number of Shares

688,460

Previous 688,460 -0.0%

Holding current value

$98.9 Million

Previous $124 Million 23.76%

% of portfolio

4.99%

Previous 7.81%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$142.64 - $194.44 $14.3 Million - $19.4 Million	-100,000 Reduced 12.68%	688,460 $124 Million
Q4 2024 Feb 14, 2025	SELL	$156.64 - $199.61 $31.3 Million - $39.9 Million	-200,000 Reduced 20.23%	788,460 $124 Million
Q3 2023 Nov 14, 2023	SELL	$108.51 - $130.22 $195,318 - $234,396	-1,800 Reduced 0.18%	988,460 $115 Million
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $3.52 Million - $5.85 Million	44,853 Added 4.74%	990,260 $116 Million
Q1 2023 May 15, 2023	SELL	$72.39 - $84.27 $3.93 Million - $4.58 Million	-54,330 Reduced 5.43%	945,407 $75.7 Million
Q4 2022 Feb 03, 2023	SELL	$63.14 - $79.9 $1.18 Million - $1.49 Million	-18,651 Reduced 1.83%	999,737 $79.2 Million
Q3 2022 Nov 14, 2022	SELL	$64.85 - $82.4 $4.99 Million - $6.35 Million	-77,019 Reduced 7.03%	1,018,388 $71 Million
Q2 2022 Aug 10, 2022	BUY	$48.93 - $73.47 $11.2 Million - $16.8 Million	229,157 Added 26.45%	1,095,407 $71.9 Million
Q1 2022 May 16, 2022	BUY	$51.99 - $72.11 $45 Million - $62.5 Million	866,250 New	866,250 $57.6 Million

Others Institutions Holding KRYS

# of Institutions

310

Shares Held

24.7M

Call Options Held

419K

Put Options Held

489K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $3.69B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Frazier Life Sciences Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Frazier Life Sciences Management, L.P. with notifications on news.

Account

Frazier Life Sciences Management, L.P. Krystal Biotech, Inc. Transaction History